地氯雷他定联合卡介菌多糖核酸注射液治疗慢性荨麻疹的临床效果  

Clinical Effect of Desloratadine Combined with BCG Polysaccharide Nucleic Acid Injection for the Treatment of Chronic Urticaria

作　　者：沈万翠 SHEN Wancui(Rizhao City Skin Disease Prevention and Treatment,Rizhao 276800,China)

机构地区：[1]日照市皮肤病防治所,山东日照276800

出　　处：《中国医药指南》2023年第24期21-24,共4页Guide of China Medicine

摘　　要：目的就慢性荨麻疹采用地氯雷他定联合卡介菌多糖核酸注射液治疗的效果进一步分析,为患者的病情管理提供有力的解决方案。方法将2021年1月至2022年6月本院收治的120例慢性荨麻疹患者作为研究对象,按照随机数表法分为两组,对照组采用地氯雷他定单一用药治疗,观察组采用地氯雷他定联合卡介菌多糖核酸注射液治疗,对比两组的干预成果。结果观察组患者的治愈率为81.66%,对照组则为61.66%,两组对比差异有统计学意义(P<0.05)。观察组患者实验室检查结果较优,观察组患者的CD_(3)^(+)、CD_(4)^(+)、CD_(8)^(+)以及CD_(4)^(+)/CD_(8)^(+)水平均优于对照组,对比差异大(P<0.05)。对比两组患者的生活质量水平,观察组患者的评分低于对照组,对比差异大(P<0.05)。观察者组患者的发作次数和频率低于对照组,对比差异大(P<0.05)。在两组患者的疾病复发率方面,观察组低于对照组,对比差异大(P<0.05)。在满意度评价方面,观察组患者为(9.56±3.54)分,对照组则为(8.45±3.04)分,对比差异大(P<0.05)。结论针对慢性荨麻疹患者,为其实施地氯雷他定联合卡介菌多糖核酸注射液疗,不仅能够改善患者的病情状态,还有助于提升患者的机体免疫能力,同时可减少发作次数,延长发作间隔时间,积极控制复发率,获得良好的预后效果,继而提升生活质量。Objective To use desloratadine combined with BCG polysaccharucleic acid injection for the treatment of chronic urticaria,further analyze the actual efficacy of the treatment measures,and provide a powerful solution for the patients'condition management.Methods A total of 120 patients with chronic urticaria from January 2021 to June 2022 were divided into two groups according to the random number table method.The control group was desloratadine,and the observation group was desloratadine combined with BCG polysaccharonucleic acid injection,and the intervention results were compared.Results The cure rate of patients in the observation group was 81.66%in the observation group and was 61.66%in the control group,showing the difference between the two groups(P<0.05).The laboratory results of the patients in the observation group were better,the level of the CD_(3)^(+),CD_(4)^(+),CD_(8)^(+)and CD_(4)^(+)/CD_(8)^(+)in the observation group were better than those of the control group,and there were differences between the two groups(P<0.05).In the level of the comparison patients,the score level of the patients in the observation group was lower than that of the control group,and there was a difference between the two groups(P<0.05).The frequency and frequency of the control group showed that the treatment achieved a certain control effect,and the comparison between the two groups was different(P<0.05).In terms of the disease recurrence rate of the comparison patients,the observation group was lower than the control group,and there was a difference between the two groups(P<0.05).The satisfaction evaluation in the observation group was(9.56±3.54)scores and was(8.45±3.04)scores in the control group,respectively(P<0.05).Conclusion For patients with chronic urticaria,for the implementation of desloratadine combined BCG polysaccharide injection therapy,not only can improve patient condition,but also helps to improve the patient's immune ability,and can reduce the number of attacks,extend the attack interval time,control the

关 键 词：地氯雷他定 卡介菌多糖核酸注射液 慢性荨麻疹 免疫 复发 

分 类 号：R758.24[医药卫生—皮肤病学与性病学]